Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Calgary

$120,000.00

Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer

EF 2024-25

Résumé
Breast cancer is the most common cancer affecting women in Canada and is the second leading cause of death from cancer in Canadian women. This translates into one Canadian woman succumbing to this disease every 90 minutes. In recent years, advances to cancer treatment have been made with immunotherapies using effector T cells, a type of immune cell. The ability to genetically manipulate effector T cells have made them powerful killers of tumour cells. However, only a fraction of breast cancer patients have benefited from these treatments. In breast cancer, local immunosuppressive mechanisms and the limited capacity of T cells to infiltrate breast cancer limit the effector T cells' ability to reach their targets and eliminate tumour cells. Consequently, many patients suffer from untreatable relapses and have exhausted their treatment options. Thus, alternative targets and treatments that give patients a second chance to eradicate cancer are urgently needed. Our research has revealed that type 2 innate lymphoid cells (ILC2s), another type of immune cell, have the potential to counteract the tumour's immunosuppressive mechanisms and improve the recruitment and functions of effector T cells to eradicate breast tumours. Here, we propose to engineer ILC2s to further increase their capacity to enhance T cell-based treatment efficacy in breast cancer. Specifically, this project seeks to i) use cutting-edge genome editing tools to genetically engineer ILC2s and verify the successful engineering and the functions of these engineered ILC2s in cell culture, and ii) evaluate the ability of these engineered ILC2s to promote T cell immunotherapy-driven tumour killing in preclinical models. Collectively, this innovative approach has the potential to boost T cell-based treatment efficacy for breast cancer, improving breast cancer patient outcomes.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518131
Name
Kinzel Megan E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Flow Cytometry; Genetic Engineering; Immunotherapy; Innate Lymphoid Cells; Tumour Microenvironment
Abstract
Breast cancer is the most common cancer affecting women in Canada and is the second leading cause of death from cancer in Canadian women. This translates into one Canadian woman succumbing to this disease every 90 minutes. In recent years, advances to cancer treatment have been made with immunotherapies using effector T cells, a type of immune cell. The ability to genetically manipulate effector T cells have made them powerful killers of tumour cells. However, only a fraction of breast cancer patients have benefited from these treatments. In breast cancer, local immunosuppressive mechanisms and the limited capacity of T cells to infiltrate breast cancer limit the effector T cells' ability to reach their targets and eliminate tumour cells. Consequently, many patients suffer from untreatable relapses and have exhausted their treatment options. Thus, alternative targets and treatments that give patients a second chance to eradicate cancer are urgently needed. Our research has revealed that type 2 innate lymphoid cells (ILC2s), another type of immune cell, have the potential to counteract the tumour's immunosuppressive mechanisms and improve the recruitment and functions of effector T cells to eradicate breast tumours. Here, we propose to engineer ILC2s to further increase their capacity to enhance T cell-based treatment efficacy in breast cancer. Specifically, this project seeks to i) use cutting-edge genome editing tools to genetically engineer ILC2s and verify the successful engineering and the functions of these engineered ILC2s in cell culture, and ii) evaluate the ability of these engineered ILC2s to promote T cell immunotherapy-driven tumour killing in preclinical models. Collectively, this innovative approach has the potential to boost T cell-based treatment efficacy for breast cancer, improving breast cancer patient outcomes.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kinzel, Megan E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~